Targeted thermosensitive liposomes: An attractive novel approach for increased drug delivery to solid tumors

Expert Opinion on Drug Delivery

Volumn 11, Issue 1, 2014, Pages 83-100

  Dicheva, Bilyana M ^a   Koning, Gerben A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Drug delivery; Hyperthermia; Targeted thermosensitive liposomes; Triggered release

Indexed keywords

ANTINEOPLASTIC AGENT; CALCEIN; DOXORUBICIN; FLUORINE 18; GALLIUM 67; HISTAMINE; IMMUNOLIPOSOME; INDIUM 111; INTERLEUKIN 2; IODINE 123; IODINE 131; LIPOSOME; LISTERIOLYSIN; MACROGOL 2000; NANOCARRIER; RADIOSENSITIZING AGENT; TECHNETIUM 99M; THALLIUM 201; THERMODOX; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ALOPECIA; ANOREXIA; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DNA REPAIR; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EXTRAVASATION; DRUG FORMULATION; DRUG RELEASE; FATIGUE; FEVER; HEAT SENSITIVITY; HUMAN; HYPERTHERMIC THERAPY; LEUKOPENIA; LYMPHOCYTOPENIA; NAUSEA; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONLINE MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; THERMOMETRY; TUMOR VASCULARIZATION; ANIMAL; HEAT; MOLECULAR IMAGING; MULTIMODALITY CANCER THERAPY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HOT TEMPERATURE; HUMANS; HYPERTHERMIA, INDUCED; LIPOSOMES; MOLECULAR IMAGING; NEOPLASMS;

EID: 84890727853     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.866650     Document Type: Review

References (123)

1. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev 2013;65(1):36-48
2. Koning GA, Krijger GC. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med Chem 2007;7(4):425-40
3. Charrois GJ, Allen TM. Rate of biodistribution of STEALTH liposomes to tumor and skin: Influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta 2003;1609(1):102-8
4. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000;65(1-2):271-84
5. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998;95(8):4607-12
6. Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013;73(8):2412-17
7. Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001;7(2):243-54
8. Seynhaeve AL, Hoving S, Schipper D, et al. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res 2007;67(19):9455-62
9. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/ Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15(3):440-9
10. Mills JK, Needham D. The materials engineering of temperature-sensitive liposomes. Methods Enzymol 2004;387:82-113
11. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperaturesensitive liposome for use with mild hyperthermia: Characterization and testing in a human tumor xenograft model. Cancer Res 2000;60(5):1197-201
12. Tsong TY. Kinetics of the crystallineliquid crystalline phase transition of dimyristoyl L-Alpha-lecithin bilayers. Proc Natl Acad Sci USA 1974;71(7):2684-8
13. Park JW, Hong K, Kirpotin DB, et al. Immunoliposomes for cancer treatment. Adv Pharmacol 1997;40:399-435
14. Fretz MM, Hogset A, Koning GA, et al. Cytosolic delivery of liposomally targeted proteins induced by photochemical internalization. Pharma Res 2007;24(11):2040-7
15. Gaber MH. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia. J Biochem Mol Biol Biophys 2002;6(5):309-14
16. Kullberg M, Mann K, Owens JL. A twocomponent drug delivery system using Her-2-Targeting thermosensitive liposomes. J Drug Target 2009;17(2):98-107
17. Kullberg M, Owens JL, Mann K. Listeriolysin O enhances cytoplasmic delivery by Her-2 targeting liposomes. J Drug Target 2010;18(4):313-20
18. Puri A, Kramer-Marek G, Campbell-Massa R, et al. HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res 2008;18(4):293-307
19. Dicheva BM, Hagen TL, Li L, et al. Cationic thermosensitive liposomes: A novel dual targeted heat-Triggered drug delivery approach for endothelial and tumor Cells. Nano Lett 2013;13(6):2324-31
20. Negussie AH, Miller JL, Reddy G, et al. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Release 2010;143(2):265-73
21. Smith B, Lyakhov I, Loomis K, et al. Hyperthermia-Triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). J Control Release 2011;153(2):187-94
22. Reinhold HS, van der Zee J, Faithfull NS, et al. Use of the Pomp-Siemens hyperthermia cabin. Natl Cancer Inst Monogr 1982;61:371-5
23. Grull H, Langereis S. Hyperthermia-Triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound. J Control Release 2013 Jul 20;161(2):317-27
24. Peller M, Schwerdt A, Hossann M, et al. MR characterization of mild hyperthermia-induced gadodiamide release from thermosensitive liposomes in solid tumors. Investig Radiol 2008;43(12):877-92
25. Tagami T, Foltz WD, Ernsting MJ, et al. MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials 2011;32(27):6570-8
26. Viglianti BL, Ponce AM, Michelich CR, et al. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med 2006;56(5):1011-18
27. de Smet M, Heijman E, Langereis S, et al. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: An in vivo proof-of-concept study. J Control Release 2013;150(1):102-10
28. Ranjan A, Jacobs GC, Woods DL, et al. Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. J Control Release 2012;158(3):487-94
29. Stakhursky VL, Arabe O, Cheng KS, et al. Real-Time MRI-guided hyperthermia treatment using a fast adaptive algorithm. Phys Med Biol 2009;54(7):2131-45
30. Song CW, Shakil A, Griffin RJ, Okajima K. Improvement of tumor oxygenation status by mild temperature hyperthermia alone or in combination with carbogen. Semin Oncol 1997;24(6):626-32
31. de Bruijne M, Wielheesen DH, van der Zee J, et al. Benefits of superficial hyperthermia treatment planning: Five case studies. Int J Hyperthermia 2007;23(5):417-29
32. Franckena M, Canters R, Termorshuizen F, et al. Clinical implementation of hyperthermia treatment planning guided steering: A cross over trial to assess its current contribution to treatment quality. Int J Hyperthermia 2010;26(2):145-57
33. Horsman MR, Overgaard J. Hyperthermia: A potent enhancer of radiotherapy. Clin Oncol (R Coll Radiol) 2007;19(6):418-26
34. Van Der Zee J, De Bruijne M, Mens JW, et al. Reirradiation combined with hyperthermia in breast cancer recurrences: Overview of experience in Erasmus MC. Int J Hyperthermia 2010;26(7):638-48
35. van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000;355(9210):1119-25
36. van der Zee J, van Rhoon GC. Cervical cancer: Radiotherapy and hyperthermia. Int J Hyperthermia 2006;22(3):229-34
37. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21(23):4270-6
38. Issels RD, Lindner LH, Verweij J, et al. Neo-Adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-Tissue sarcoma: A randomised phase 3 multicentre study. Lancet Oncol 2010;11(6):561-70
39. Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 1999;15(2):79-107
40. al-Shabanah OA, Osman AM, al-Harbi MM, et al. Enhancement of doxorubicin-induced cytotoxicity by hyperthermia in Ehrlich ascites cells. Chemotherapy 1994 May-Jun;40(3):188-94
41. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002;43(1):33-56
42. Urano M, Begley J, Reynolds R. Interaction between adriamycin cytotoxicity and hyperthermia: Growth-phase-dependent thermal sensitization. Int J Hyperthermia 1994;10(6):817-26
43. Eppink B, Krawczyk PM, Stap J, Kanaar R. Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies. Int J Hyperthermia 2012;28(6):509-17
44. Kampinga HH, Dikomey E. Hyperthermic radiosensitization: Mode of action and clinical relevance. Int J Radiat Biol 2001;77(4):399-408
45. Krawczyk PM, Eppink B, Essers J, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA 2011;108(24):9851-6
46. Horsman MR, Overgaard J. Can mild hyperthermia improve tumour oxygenation? Int J Hyperthermia 1997;13(2):141-7
47. Karino T, Koga S, Maeta M. Experimental studies of the effects of local hyperthermia on blood flow, oxygen pressure and pH in tumors. Jpn J Surg 1988;18(3):276-83
48. Hauck ML, Coffin DO, Dodge RK, et al. A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. Int J Hyperthermia 1997;13(3):307-16
49. Fujiwara K, Watanabe T. Effects of hyperthermia, radiotherapy and thermoradiotherapy on tumor microvascular permeability. Acta Pathol Jpn 1990 Feb;40(2):79-84
50. Gaber MH, Wu NZ, Hong K, et al. Thermosensitive liposomes: Extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 1996;36(5):1177-87
51. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: Effect of particle size. Cancer Res 2000;60(16):4440-5
52. Li L, ten Hagen TL, Bolkestein M, et al. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J Control Release 2013;167(2):130-7
53. Huang SK, Stauffer PR, Hong K, et al. Liposomes and hyperthermia in mice: Increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 1994;54(8):2186-91
54. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001;61(7):3027-32
55. Matteucci ML, Anyarambhatla G, Rosner G, et al. Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin Cancer Res 2000;6(9):3748-55
56. May JP, Li SD. Hyperthermia-induced drug targeting. Expert opin Drug Deliv 2013;10(4):511-27
57. Dreher MR, Liu W, Michelich CR, et al. Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer Res 2007;67(9):4418-24
58. Moktan S, Perkins E, Kratz F, Raucher D. Thermal targeting of an acid-sensitive doxorubicin conjugate of elastin-like polypeptide enhances the therapeutic efficacy compared with the parent compound in vivo. Mol Cancer Ther 2012;11(7):1547-56
59. Bidwell GL III, Perkins E, Raucher D. A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth. Cancer Lett 2012;319(2):136-43
60. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978;202(4374):1290-3
61. de Smet M, Langereis S, van den Bosch S, Grull H. Temperature-sensitive liposomes for doxorubicin delivery under MRI guidance. J Control Release 2010;143(1):120-7
62. Li L, ten Hagen TL, Schipper D, et al. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release 2010;143(2):274-9
63. Lindner LH, Eichhorn ME, Eibl H, et al. Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res 2004;10(6):2168-78
64. Gaber MH, Hong K, Huang SK, Papahadjopoulos D. Thermosensitive sterically stabilized liposomes: Formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma. Pharma Res 1995;12(10):1407-16
65. Unezaki S, Maruyama K, Takahashi N, et al. Enhanced delivery and antitumor activity of doxorubicin using longcirculating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia. Pharma Res 1994;11(8):1180-5
66. Landon CD, Park J, Needham D, Dewhirst MW. Nanoscale drug delivery and hyperthermia: The materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. Open Nanomed J 2011(3):38-64
67. Mills JK, Needham D. Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochim Biophys Acta 2005;1716(2):77-96
68. Manzoor AA, Lindner LH, Landon CD, et al. Overcoming limitations in nanoparticle drug delivery: Triggered, intravascular release to improve drug penetration into tumors. Cancer Res 2012;72(21):5566-75
69. Hossann M, Syunyaeva Z, Schmidt R, et al. Proteins and cholesterol lipid vesicles are mediators of drug release from thermosensitive liposomes. J Control Release 2012;162(2):400-6
70. Poon RT, Borys N. Lyso-Thermosensitive liposomal doxorubicin: A novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother 2009;10(2):333-43
71. Al-Jamal WT, Al-Ahmady ZS, Kostarelos K. Pharmacokinetics & tissue distribution of temperature-sensitive liposomal doxorubicin in tumor-bearing mice triggered with mild hyperthermia. Biomaterials 2012;33(18):4608-17
72. Hossann M, Wang T, Wiggenhorn M, et al. Size of thermosensitive liposomes influences content release. J Control Release 2010;147(3):436-43
73. Li L, Ten Hagen TL, Hossann M, et al. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy. J Control Release 2013;168(2):142-50
74. Tagami T, Ernsting MJ, Li SD. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin. J Control Release 2011;152(2):303-9
75. Tagami T, Ernsting MJ, Li SD. Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system. J Control Release 2011 Sep 25;154(3):290-7
76. Tagami T, May JP, Ernsting MJ, Li SD. A thermosensitive liposome prepared with a Cu(2)(+) gradient demonstrates improved pharmacokinetics, drug delivery and antitumor efficacy. J Control Release 2012;161(1):142-9
77. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects. Bioconjug Chem 2010;21(5):797-802
78. Chen Q, Tong S, Dewhirst MW, Yuan F. Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Mol Cancer Ther 2004;3(10):1311-17
79. Seynhaeve AL, Eggermont AM, ten Hagen TL. TNF and manipulation of the tumor cell-stromal interface: "ways to make chemotherapy effective". Front Biosci 2008;13:3034-45
80. Ponce AM, Viglianti BL, Yu D, et al. Magnetic resonance imaging of temperature-sensitive liposome release: Drug dose painting and antitumor effects. J Natl Cancer Inst 2007;99(1):53-63
81. Dromi S, Frenkel V, Luk A, et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 2007;13(9):2722-7
82. Drummond DC, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999 Dec;51(4):691-743
83. Mastrobattista E, Koning GA, Storm G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev 1999;40(1-2):103-27
84. Wicki A, Rochlitz C, Orleth A, et al. Targeting tumor-Associated endothelial cells: Anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res 2012;18(2):454-64
85. Allen TM. Ligand-Targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2(10):750-63
86. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science 2004;303(5665):1818-22
87. Kirpotin D, Park JW, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human breast cancer cells in vitro. Biochemistry 1997;36(1):66-75
88. Park JW, Hong K, Carter P, et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 1995;92(5):1327-31
89. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-Targeted liposomal drugs. Cancer Res 2002;62(24):7190-4
90. Koning GA, Morselt HW, Gorter A, et al. Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases. Pharma Res 2001;18(9):1291-8
91. Koning GA, Morselt HW, Gorter A, et al. Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison. Pharma Res 2003;20(8):1249-57
92. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006;312(5):549-60
93. Koning GA, Schiffelers RM, Storm G. Endothelial cells at inflammatory sites as target for therapeutic intervention. Endothelium 2002;9(3):161-71
94. Drummond DC, Hong K, Park JW, et al. Liposome targeting to tumors using vitamin and growth factor receptors. Vitam Horm 2000;60:285-332
95. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8(4):1172-81
96. Sugano M, Egilmez NK, Yokota SJ, et al. Antibody targeting of doxorubicinloaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 2000;60(24):6942-9
97. Zhao G, Rodriguez BL. Molecular targeting of liposomal nanoparticles to tumor microenvironment. Int J Nanomedicine 2013;8:61-71
98. Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: From the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci 2009;98(2):411-29
99. Schiffelers RM, Koning GA, ten Hagen TL, et al. Anti-Tumor efficacy of tumor vasculature-Targeted liposomal doxorubicin. J Control Release 2003;91(1-2):115-22
100. Pastorino F, Brignole C, Marimpietri D, et al. Vascular damage and antiangiogenic effects of tumor vesseltargeted liposomal chemotherapy. Cancer Res 2003;63(21):7400-9
101. Sapra P, Allen TM. Ligand-Targeted liposomal anticancer drugs. Prog Lipid Res 2003;42(5):439-62
102. Loi M, Marchio S, Becherini P, et al. Combined targeting of perivascular and endothelial tumor cells enhances antitumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release 2010;145(1):66-73
103. Moura V, Lacerda M, Figueiredo P, et al. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: Impact on the treatment of breast cancer. Breast Cancer Res Treat 2012;133(1):61-73
104. Xiong XB, Huang Y, Lu WL, et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 2005;107(2):262-75
105. Zhao H, Wang JC, Sun QS, et al. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J Drug Target 2009;17(1):10-18
106. Kalra AV, Campbell RB. Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting. Pharma Res 2006;23(12):2809-17
107. Strieth S, Eichhorn ME, Werner A, et al. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clin Cancer Res 2008;14(14):4603-11
108. Campbell RB, Fukumura D, Brown EB, et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 2002;62(23):6831-6
109. Ho EA, Ramsay E, Ginj M, et al. Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties. J Pharm Sci 2010;99(6):2839-53
110. Abu Lila AS, Kizuki S, Doi Y, et al. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dualtargeting approach in a murine solid tumor model. J Control Release 2009;137(1):8-14
111. Schmitt-Sody M, Strieth S, Krasnici S, et al. Neovascular targeting therapy: Paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003;9(6):2335-41
112. Wu J, Lee A, Lu Y, Lee RJ. Vascular targeting of doxorubicin using cationic liposomes. Int J Pharm 2007;337(1-2):329-35
113. Mamot C, Drummond DC, Greiser U, et al. Epidermal growth factor receptor (EGFR)-Targeted immunoliposomes mediate specific and efficient drug delivery to EGFR-And EGFRvIIIoverexpressing tumor cells. Cancer Res 2003;63(12):3154-61
114. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptortargeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005;65(24):11631-8
115. Mamot C, Ritschard R, Wicki A, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: A phase 1 dose-escalation study. Lancet Oncol 2012;13(12):1234-41
116. Lundberg BB, Griffiths G, Hansen HJ. Cellular association and cytotoxicity of doxorubicin-loaded immunoliposomes targeted via Fab' fragments of an anti-CD74 antibody. Drug Deliv 2007;14(3):171-5
117. Brignole C, Marimpietri D, Gambini C, et al. Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett 2003;197(1-2):199-204
118. Weinstein JN, Eger RR, Covell DG, et al. The pharmacology of monoclonal antibodies. Ann NY Acad Sci 1987;507:199-210
119. Mastrobattista E, Koning GA, van Bloois L, et al. Functional characterization of an endosomedisruptive peptide and its application in cytosolic delivery of immunoliposomeentrapped proteins. J Biol Chem 2002;277(30):27135-43
120. Simoes S, Moreira JN, Fonseca C, et al. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 2004;56(7):947-65
121. Fattahi H, Laurent S, Liu F, et al. Magnetoliposomes as multimodal contrast agents for molecular imaging and cancer nanotheragnostics. Nanomedicine (Lond) 2011;6(3):529-44
122. Pradhan P, Giri J, Rieken F, et al. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release 2010 Feb 25;142(1):108-21
123. Kikumori T, Kobayashi T, Sawaki M, Imai T. Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast cancer Res Treat 2009;113(3):435-41